BioCentury | Feb 26, 2020
Product Development

COVID-19: A growing list of new vaccines and therapies in development

As the response to the COVID-19 outbreak unfolds, BioCentury is tracking the new vaccines and therapeutics in development against the coronavirus and updating the list on an ongoing basis. Repurposed agents being tested for activity...
BC Extra | Dec 27, 2019
Company News

With Zejula’s third local approval, Zai ready for mainland China launch

China’s approval of Zejula gives Zai Lab its first approval in mainland China and allows the company to start marketing the PARP inhibitor in the largest of the three markets in which it holds rights....
BC Week In Review | Aug 31, 2018
Company News

SEC not recommending enforcement action against Sinovac

Sinovac Biotech Ltd. (NASDAQ:SVA) said the SEC will not recommend pursuit of enforcement action against the company following an investigation into allegations that Sinovac employees violated federal securities laws by making “improper payments” to Chinese...
BC Week In Review | Jul 13, 2018
Financial News

Sinovac Terminates Take-Private Deal, Raises $86.7M

Vaccines company Sinovac Biotech Ltd. (NASDAQ:SVA) said July 3 it raised $86.7 million in a private placement and terminated a planned deal to take the company private. A special committee formed by the company's board...
BC Extra | Jul 3, 2018
Financial News

Sinovac terminates take-private deal, raises $86.7M

Vaccines company Sinovac Biotech Ltd. (NASDAQ:SVA) said it raised $86.7 million in a private placement and terminated a planned deal to take the company private. A special committee formed by the company's board determined that...
BC Week In Review | Nov 30, 2017
Clinical News

Sinovac reports Phase III data for varicella vaccine

In September, Sinovac Biotech Ltd. (NASDAQ:SVA) reported top-line data from a Phase III trial in about 6,000 healthy children aged 1-12 showing that its Varicella vaccine prevented varicella zoster virus (VZV) infection in 87.1% of...
BC Week In Review | Aug 11, 2017
Company News

Sinobioway provides update on its bid to acquire Sinovac

A consortium led by Shandong Sinobioway Biomedicine Co. Ltd. (SZSE:002581) said it submitted all required documents to Sinovac Biotech Ltd. (NASDAQ:SVA) to prove it has sufficient funds to finance an $8 per share bid to...
BC Week In Review | Jul 7, 2017
Company News

Sinovac going private

Sinovac Biotech Ltd. (NASDAQ:SVA) said it will be acquired by an investor syndicate led by Chairman, President and CEO Weidong Yin and SAIF Partners for $7 per share, or about $401.8 million. Other investors include...
BC Extra | Jul 3, 2017
Company News

Sinobioway counters Sinovac buyout offer

A consortium led by Shandong Sinobioway Biomedicine Co. Ltd. (SZSE:002581) has entered a counteroffer to acquire Sinovac Biotech Ltd. (NASDAQ:SVA), which said last week an investor syndicate led by its Chairman, President and CEO Weidong...
BC Extra | Jun 26, 2017
Financial News

Sinovac going private

Sinovac Biotech Ltd. (NASDAQ:SVA) said it will be acquired by an investor syndicate led by Chairman, President and CEO Weidong Yin and SAIF Partners for $7 per share, or about $401.8 million. Other investors include...
Items per page:
1 - 10 of 106